Barclays
MBX

Barclays’s MBX Biosciences MBX Stock Holding History

Barclays’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.85M Buy
87,854
+76,016
+642% +$2.65M ﹤0.01% 1861
2026
Q1 		$353K Sell
11,838
-40,853
-78% -$1.39M ﹤0.01% 3376
2025
Q4 		$1.66M Buy
52,691
+31,065
+144% +$754K ﹤0.01% 3063
2025
Q3 		$378K Sell
21,626
-36,915
-63% -$494K ﹤0.01% 3969
2025
Q2 		$668K Buy
58,541
+46,723
+395% +$476K ﹤0.01% 3590
2025
Q1 		$87.2K Sell
11,818
-5,615
-32% -$59.4K ﹤0.01% 4453
2024
Q4 		$321K Buy
17,433
+1,033
+6% +$22K ﹤0.01% 4082
2024
Q3 		$426K Buy
+16,400
New +$375K ﹤0.01% 3879

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Barclays's MBX Position: Q2 2026 in Review

Barclays increased its MBX Biosciences (MBX) stake by 642% in Q2 2026, buying an estimated $2.65M and bringing the position to 87,854 shares worth $4.85M. The position accounts for ﹤0.01% of the portfolio, ranked #1861.

Barclays first reported a position in MBX in Q3 2024 and has held it in 8 quarters since. 172 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Barclays held 87,854 shares of MBX Biosciences worth $4.85M as of Q2 2026.
  • Barclays bought 76,016 MBX Biosciences shares in Q2 2026, an estimated $2.65M.
  • MBX Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1861 holding.
  • Barclays first reported a position in MBX Biosciences in Q3 2024 and has held it in 8 quarters since.
  • 172 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.